Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06143709 · ClinicalTrials.gov registry record
Precision PCI Registry
A clinical trial of Coronary Artery Disease and Percutaneous Coronary Intervention, sponsored by University of Florida.
- Active
- Registry status
- 1,643
- Enrollment target
- 1
- Study location
NCT06143709 is a study of Coronary Artery Disease and Percutaneous Coronary Intervention that is active but no longer recruiting, run by University of Florida. The registered enrollment target is 1,643 participants, above the 1,279-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (28% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06143709, a study of Coronary Artery Disease and Percutaneous Coronary Intervention, is active but no longer recruiting, sponsored by University of Florida.
- ACTIVE NOT RECRUITING
- Registry status
- 1,643 participants
- Enrollment target
- 1
- Study location
Study Summary
The feasibility and clinical benefit of using a patient's genotype to guide antiplatelet therapy prescribing has been demonstrated. However, a more precise understanding of who to genotype, what to include on a genetic testing panel, and how to change antiplatelet therapy based on genotype results and other patient-specific factors is needed to optimize the impact of genotype-guided antiplatelet therapy on patient outcomes. The Precision PCI registry is a collaboration between the University of Florida, Gainesville and Jacksonville, USA, the University of North Carolina, Chapel Hill, USA, and University of Maryland, Baltimore, USA. This registry will include a diverse population of patients who undergo Percutaneous Coronary Intervention and clinical CYP2C19 genotyping, assess clinical outcomes over 12 months and collect DNA samples for additional genotyping, and conduct pharmacodynamic analysis of platelet function in a subset of patients. Objectives of the study: 1. Define the influence of African ancestry and other patient-specific factors on clinical outcomes with genotype-guided antiplatelet therapy following PCI in a real-world setting 2. Evaluate the safety and effectiveness of genotype-guided de-escalation of antiplatelet therapy (i.e., switching to less potent antiplatelet therapy) after PCI in a real-world setting 3. Elucidate the effect(s) of genotypes beyond CYP2C19 on platelet reactivity and clinical outcomes with clopidogrel after PCI
Conditions Studied
Interventions
- OTHER DNA sample collection
Study Locations (1)
Florida
- University of Florida - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,643 participants |
| Start Date | 2020-07-17 |
| Est. Completion | 2026-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06143709
The ClinicalTrials.gov registry entry for NCT06143709 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1,643 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,279-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (28% higher). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which DNA sample collection is the first listed.
NCT06143709 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06143709 about?
NCT06143709 is a clinical study titled "Precision PCI Registry". The feasibility and clinical benefit of using a patient's genotype to guide antiplatelet therapy prescribing has been demonstrated. However, a more precise understanding of who to genotype, what to include on a genetic testing panel, and how to change antiplatelet therapy based on genotype results a...
What is the current status of trial NCT06143709?
This trial is currently active not recruiting. The enrollment target is 1,643 participants. The study started on 2020-07-17. Estimated completion is 2026-07-01.
What conditions does trial NCT06143709 study?
This clinical trial studies the following conditions: Coronary Artery Disease, Percutaneous Coronary Intervention.
What interventions are being tested in trial NCT06143709?
The interventions under investigation include: DNA sample collection (OTHER).
Who is sponsoring clinical trial NCT06143709?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06143709 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
-
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
RECRUITING · NA
-
Factors Affect Outcomes in Cardiovascular Surgery
RECRUITING
-
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health
RECRUITING · NA
-
Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.